Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00188890|
Recruitment Status : Unknown
Verified March 2016 by University Health Network, Toronto.
Recruitment status was: Recruiting
First Posted : September 16, 2005
Last Update Posted : March 21, 2016
|Condition or disease|
|Lung Cancer Mesothelioma|
Background and Purpose:
Asbestos exposure may result in several different diseases to the lung and to the lining of the lung, the so-called pleura. Mostly they are benign, but there are two common malignant diseases in people with prior asbestos exposure, the so-called mesothelioma - which originates from the pleura - and cancer of the lung. Symptoms of any of these malignant diseases generally do not appear for 10-35 years after the first asbestos exposure, and include shortness of breath, chronic or new cough, coughing of blood, chest pain or weight loss. Unfortunately, these symptoms are most often causes by very advanced diseases, when patients can no longer be cured. Currently there is no accepted tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects available. Standard of care includes regular chest radiographs, which are not sufficient to show mesothelioma or lung cancer in an early stage.
A screening CT examination, also called CAT scan, of the lungs will be performed without intravenous contrast. The CT examination as such is not an experimental procedure, CAT scans are performed routinely since decades. However, in this particular case, this albeit standard examination is performed for the purposes of research only, it is not part of standard of care. The screening CT examination of the lungs takes less than 10-20 minutes to perform.
If no abnormalities are found on the initial examinations, you will be examined with one repeat screening CT of the chest after one year.
If pleural plaques or a nodule in the lungs is seen on your baseline CT, this will lead to further testing. Quite likely (approximately 1 in 3 chance), you will be invited for a follow-up CT 3 or 6 months. Further investigations will be chosen according to standard of care and will be explained to you at the time. These will be coordinated by your physician with Dr. Marc de Perrot, Department of Thoracic Surgery.
Secondly, there is evidence in other types of cancers such as cancers of the prostate and ovary, that analysis of blood may reveal protein markers that indicate the presence of cancer in the body. A companion blood analysis study is being undertaken in an effort to discover such markers for lung cancer and mesothelioma, so that the accuracy of CT-scan diagnosis for lung cancer may be further improved.
Both at the time of your baseline screening CT and at your annual follow-up screening CT, you will be asked to provide 5 ml (approximately 2 teaspoons full) blood sample through a needle stick. A blood-taking technician employed by the University Health Network or a certified nurse will carry out this procedure. Purpose of this study is to search in the blood for so-called "markers", substances in the blood which indicate that there is a cancer in the lungs or pleura.
Most of these markers are still in development, thus your blood will be stored and analyzed at a future date.
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Observational Model:||Case Control|
|Official Title:||Early Diagnosis of Mesothelioma and Lung Cancer Following Asbestos Exposure Using Low-dose Computed Tomography|
|Study Start Date :||March 2005|
|Estimated Primary Completion Date :||March 2017|
|Estimated Study Completion Date :||March 2017|
prior occupational exposure at least 20 years ago to ASBESTOS and / or documented pleural plaques on a chest x-ray Must be 30 years of age or older. NO prior cancers, except non-melanic skin cancers
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00188890
|Contact: Demetris Patsios, MD||Tel: (416) 603-5800 ext email@example.com|
|Contact: Brenda O'Sullivan||416-340-4800 ext 5686||Brenda.O'Sullivan@uhn.on.ca|
|Princess Margaret Hospital||Recruiting|
|Toronto, Ontario, Canada|
|Contact: Demetris Patsios, MD Tel: (416) 603-5800 ext 2583 firstname.lastname@example.org|
|Contact: Brenda O'Sullivan, MD 416-340-4800 ext 5686 email@example.com|
|Principal Investigator:||Demetris Patsios, MD||University Health Network, Toronto|
|Principal Investigator:||Marc de Perrot, MD||University Health Network, Toronto|